Specialty Care Models

Specialty value-based care is moving from pilot-stage enthusiasm toward model-specific proof points and methodological scrutiny: Interwell Health reported shared savings and high quality performance in CMS’ Kidney Care Choices model, reinforcing kidney care as one of the more mature specialty VBC lanes, while oncology stakeholders are reassessing the legacy Oncology Care Model amid concerns that core evaluation methods may have distorted measured performance. At the same time, specialists are positioning themselves as essential actors in the next phase of VBC—across nephrology, oncology, dementia care under GUIDE, and other high-cost chronic conditions—creating pressure on CMS under the Trump administration’s current leadership to refine attribution, benchmarking, risk adjustment, and prior authorization infrastructure so specialty models can scale without mispricing risk or burdening practices. See: [Interwell kidney model results](https://news.google.com/rss/articles/CBMivgFBVV95cUxOYjlSVHZsSzFZS1F3WE1lWm9OcVR4bjJRdWtJTXA0djVJLTNLZk05dFdCcnl6d0ZWQmlEUzE1RzdNNVlkaXZ1eFZ0dmJ4YmNSZDVCNkkyRGdjV3JCN3VMMEMxS2xrejJMZUo2WUlXeDZuT3VkMzcxTEJmUjUwTW1MZ2hBZ3RZbUN